incidence of febrile convulsions was also similar,9 but it is worth remembering that in children of this age convulsions are 10 times more common with natural measles than after vaccination. 10 An additional symptom to be reported after the vaccine was parotitis, which occurred in less than 1% of children-usually between two and three weeks after the vaccine. Some of these cases may have resulted from natural infection, but the appreciable clustering suggests that they were probably caused by the vaccine. Many of the symptoms reported were trivial, but parents should be warned about the possibility ofa reaction a week after vaccination and reassured that the child will not come to harm and is not infectious.
In 1987 three cases of meningoencephalitis were reported from Canada after the combined vaccine."I All recovered without sequelae.1" This was calculated to occur in one in 100 000 doses ofvaccine, which might mean six cases a year in Britain if uptake of the vaccine is as high as we hope. At the moment there are about 1000 cases a year of meningoencephalitis caused by mumps, some of which have an unfavourable outcome.
To assess the impact of the new vaccine a comprehensive surveillance programme has already been set up. Uptake of vaccination by age and district will be monitored; susceptibility to rubella and infections in pregnancy, cases of congenital rubella syndrome, and terminations of pregnancy for rubella will continue to be recorded and investigated. Rubella and mumps will be notifiable. A scheme to monitor prevalence of antibodies to measles, mumps, and rubella by age in about 800 yearly serum specimens from public health laboratories began in 1987 (p 770). This surveillance should identify susceptible cohorts to allow their selective vaccination if necessary.
A few years ago doubts were expressed about changing our rubella vaccination policy.'2 13 It was feared that an uptake of vaccination of around 60% in the second year of life-the figure then for measles vaccine-might increase the age incidence of rubella and thus the risk of rubella in pregnancy. In England and Wales, however, the uptake of measles vaccine reached 71% in 1986, and further steps have been taken to achieve the target of 90% by 1990. Immunisation is now included in the review process of regional health authorities and the Department ofHealth and Social Security.
Each district now has a named immunisation coordinator who is responsible for immunisation by both general practitioners and clinical medical officers. The coordinators' duties include training medical and nursing staff, investigating and remedying poor local immunisation rates, and establishing a positive attitude towards immunisation in-professionals and the public.
In some districts uptake of measles vaccine has already reached 90%, but in others it is still unacceptably low. In 1987 around 42 000 cases of measles were notified in England and Wales; this was the lowest yearly figure recorded, but in the first half of 1988 notifications already exceeded 52 000 and by May six children had died. Since then three more have died, which may result in 1988 having more than the average 20 deaths a year. After 20 years of measles vaccination this is a poor performance. Britain lags behind most developed countries-and, it must be said, many developing countries. The introduction of the new vaccine must provide the impetus to improve our record. Every child without a valid contraindication-and this means 98% of all children-is entitled to vaccination against three preventable diseases and their potentially disastrous consequences. Silent myocardial ischaemia A lot around but not easy to suspect
We have known for years that patients with coronary artery disease may have no symptoms' and that the electrocardiographic features of ischaemia may be induced by exercise without accompanying angina.2 Nevertheless, such "silent ischaemia" has only recently been recognised to be an important feature of ischaemic heart disease.36 Silent ischaemia is defined as "objective evidence for myocardial ischaemia in the absence of angina or equivalent symptoms," and its prevalence is unknown,7 although over a quarter ofmyocardial infarctions are unrecognised and half of them cause no symptoms at all.8 Deaths from ischaemic heart disease (over 150 000 yearly in England and Wales) are often sudden and occur in people without previous symptoms. 9 Cohn has estimated the frequency in the North American population of three categories of people with silent ischaemia who may be at such a risk.'0 People of type 1 have no symptoms and no history of myocardial infarction or angina (1-2 million middle aged men); those of type 2 are symptomless survivors of myocardial infarction (50 000 a year); and patients of type 3 have angina together with episodes of silent ischaemia (around 3 million). Presumably the proportions in Britain are comparable, although the mortality from ischaemic heart disease is higher here. " Silent ischaemia may be elicited during standard stress testing such as electrocardiographic exercise tests,'2 atrial pacing,'3 thallium stress redistribution scintigraphy,'4 and exercise radionuclide ventriculography. I5 Ambulatory electrocardiographic monitoring of changes in the ST segment during normal activities has, however, provided some of the most important data.16-24 Such electrocardiographic changes have been validated by comparison with measurements of myocardial perfusion by using positron emission tomography with rubidium-82.'8 25 None the less, the selection of patients is important4 because false positive responses may occur in those who are apparently healthy.2627 Therefore validated equipment must be used to reproduce the ST segment without distortion.2829 Silent ischaemia may also be detected by ambulatory monitoring of the changes in the pulmonary artery diastolic pressure. ' Data from ambulatory monitoring have consistently shown that almost two thirds of transient ischaemia episodes in patients with stable angina cause no symptoms.'"23 Similar episodes may be detected in symptomless patients with coronary artery disease.24 Most of these episodes occur daily during activities, at rest, and during sleep. 16 17192324 Underlying mental stress may be an important provocative factor,'923243' as smoking may be.'6 32 Most episodes of silent ischaemia are short lived, but some may be prolonged.'82224 Many develop at low heart rates without any preceding rise in rate,'82124 although this has been disputed.20 Nevertheless, a primary reduction in myocardial blood flow rather than an increase in demand seems to be responsible for many episodes, possibly related to endothelial dysfunction in the atheromatous coronary arteries. 33 Silent as well as symptomatic ischaemia has a circadian rhythm, with a peak incidence around waking and the few hours thereafter.22 24 3 This parallels other important rhythms including those of the incidence of myocardial infarction35 and sudden death. 36 The incidence of silent ischaemia also varies considerably in an individual person.'837 All these findings have important implications for the doctor assessing the patient and evaluating the effects of treatment.
Possibly, silent ischaemia represents less severe ischaemia than the symptomatic form, although the evidence is weak.4192238 Patients with silent ischaemia may also have impaired responses to pain39 as in diabetes,4' but the mechanisms in most patients are obscure.
Asymptomatic ischaemia during stress testing carries an adverse prognosis,'2 542 as does silent ischaemia in unstable angina.434 Preliminary data also suggest that episodic silent ischaemia carries a poor prognosis in stable coronary artery disease.45 So should we be actively searching for and treating silent ischaemia?
Given the accumulating evidence that ischaemia, whether silent or not, carries a poor prognosis in patients with known coronary artery disease,'2 154245 it is justifiable to follow an active policy, even in patients who are totally free of symptoms.' 24 Conventional assessment with exercise testing provides a guide to its frequency,6 46and ambulatory monitoring may be additionally valuable in selected patients,533 but neither method is suitable for mass screening.4 Hence until we have more accurate non-invasive means for detecting coronary artery disease most subjects with silent and undiscovered disease will be difficult to identify.
In patients with known silent or symptomatic ischaemia reducing or eliminating the "total ischaemic burden"6 10 seems to be desirable, though this approach is untested and has been viewed with scepticism.647 Fortunately, the drugs used to treat symptomatic ischaemia also reduce silent ischaemia,6 1 but larger doses may be required to eliminate it, with their attendant problems ofside effects and compliance. The role of coronary bypass surgery and percutaneous transluminal coronary angioplasty in patients with silent ischaemia is undefined. None the less, the prognosis is still largely related to the severity of the disease '2 15 
